News:Research and scientific results

The work, led by the BBRC and published in Alzheimer’s & Dementia, has been pivotal in securing the European Medicines Agency's approval of the Centiloid metric as a valid biomarker for Alzheimer’s disease.

The results are compiled in a study published in iScience, led by the Hospital del Mar Medical Research Institute and the Barcelonaβeta Brain Research Center, center of the Pasqual Maragall Foundation.

The data have been compared with Alzheimer's biomarkers of 2,300 people from four cohorts, including participants without cognitive alterations from the ALFA Study, promoted by the ”la Caixa” Foundation.

Thanks to this neuroimaging technique, widely used in the field of research, deposits of the Alzheimer’s disease associated amyloid-β protein in the brain can be detected and evaluated.

An international initiative with the participation of the BBRC has published a protocol for the creation of Brain Health Services, intended for the attention of people without cognitive impairment who wish to preserve or improve their memory.

The results, published in The New England Journal of Medicine, confirm that lecanemab slows cognitive decline by 27% in patients in the early stages of Alzheimer's disease.

A study led by the Hospital del Mar Medical Research Institute, the Barcelonaβeta Brain Research Centre and the University of Gothenburg has compared the validity of nine biomarkers for the day-to-day diagnosis of Alzheimer's disease in hospital centres.

The research, within the European project EPAD, is headed by the Barcelonaβeta Brain Research Center (BBRC), a research center of the Pasqual Maragall Foundation, together with the University of Bristol.

In the research, led by the BBRC, 250 people without cognitive alterations from the ALFA Study, promoted by the ”la Caixa” Foundation, have participated.